Longevity research advances through epigenetic biomarkers and international scientific collaboration

Researchers are investigating the potential of epigenetic biomarkers, specifically DNA methylation (DNAm) clocks, to accelerate longevity studies. Because human clinical trials for anti-aging interventions can take decades to show results, these biomarkers may serve as essential surrogates to reflect biological age and intervention efficacy more rapidly.

A study analyzing data from 51 longitudinal interventions—ranging from lifestyle changes and supplements to pharmacological treatments like metformin and rapamycin—evaluated 16 epigenetic clocks and 94 other DNAm biomarkers. Lead author Raghav Sehgal noted that if validated, these tools could allow scientists to assess the effectiveness of therapies within months or years rather than decades.

In a related development, the 2nd International Longevity Congress is scheduled to take place in Bucharest, Romania, on September 24, 2026. Organized by the Dan Voiculescu Foundation for the Development of Romania in partnership with the International Longevity Alliance and VETEK Association, the event will host global experts from the US, Europe, Israel, India, and Saudi Arabia. The congress focuses on the concept of ‘healthspan’—extending the period of healthy and functional life—and aims to translate aging biology into practical tools for prevention, diagnosis, and personalized intervention.